Drug Search Results
More Filters [+]

mRNA-2752

Alternative Names: mrna-2752, mrna2752, mrna 2752
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs). (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/796816)

Mechanisms of Action: OX40 Stimulant,IL23 Stimulant,IL36 Stimulant

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for mRNA-2752

Countries in Clinic: Australia, Israel, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Ductal Carcinoma|Head and Neck Cancer|Intraductal Noninfiltrating Carcinoma|Lymphoma, Non-Hodgkin|Melanoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

mRNA-2752-P101

P1

Active, not recruiting

Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin|Transitional Cell Carcinoma|Triple Negative Breast Cancer

2026-03-10

NCI-2017-01320

P1

Recruiting

Intraductal Noninfiltrating Carcinoma|Ductal Carcinoma

2025-03-31

Recent News Events